Akira Yabuno

6PUBLICATIONS
27CO-AUTHORS
Predictive and prognostic markersCancer diagnosisCancer therapy (excl. chemotherapy and radiation therapy)Innate immunityChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 21, 2026
Direct comparison of 5-aminolevulinic acid photodynamic diagnosis and white light inspection for detecting peritoneal dissemination in advanced ovarian cancer: a pilot study.

Akira Yabuno, Daisuke Shintani, Masakazu Sato

|Apr 21, 2025
Histological classification of uterine cervical adenocarcinomas: Its alteration and current status.

Masanori Yasuda, Tomomi Katoh, Yu Miyama

|Nov 13, 2020
Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial.

Takashi Motohashi, Akira Yabuno, Hiroshi Michimae

|Oct 20, 2020
High expression of maternal embryonic leucine-zipper kinase (MELK) impacts clinical outcomes in patients with ovarian cancer and its inhibition suppresses ovarian cancer cells growth ex vivo.

Yuji Ikeda, Sho Sato, Akira Yabuno

|May 29, 2020
Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma.

Hirokazu Matsushita, Kosei Hasegawa, Katsutoshi Oda

|Dec 14, 2016
Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study.

Tadaaki Nishikawa, Kosei Hasegawa, Akira Yabuno

Pageof 1

Frequent Collaborators

3 joint publications

Kosei Hasegawa

3 joint publications

Masanori Yasuda

3 joint publications

Keiichi Fujiwara

2 joint publications

Sho Sato